A clinical trial of pefloxacin in prostatitis.
Thirty-one patients with initial, recurrent or chronic prostatitis mainly caused by Enterobacteriaceae were treated with pefloxacin 400 mg bd for three to 105 days (median, 28 days). The clinical and bacteriological results four weeks after the end of the treatment, were: 23 patients (74%) cured, 21 without reinfection and two with reinfection, failure in two and relapse in six patients. Side-effects, which were definitely related to pefloxacin, occurred in seven patients (22.5%) and were of a photosensitization-, muscular- and neuropsychic-type. A high eosinophil count was observed in another patient. In one patient, treatment was withdrawn because of side-effects.
Guibert
J
J
Service de Microbiologie Médicale, Hôpital Saint-Joseph, Paris, France.
Boutelier
R
R
Guyot
A
A
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015366:Pefloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011472:Prostatitis / Q000188:drug therapy*; D012008:Recurrence; D012074:Remission Induction; D013997:Time Factors
D015366:Pefloxacin